Distributions of CRP gene polymorphisms and alleles of CRP gene polymorphisms in study groups
| Patient group | Control group n (%) | P valuea | ||
|---|---|---|---|---|
| rs1205 polymorphism | TT homozygous | 15 (12.5) | 17 (17.0) | 0.429 |
| CT heterozygous | 55 (45.8) | 38 (38.0) | ||
| CC homozygous | 50 (41.7) | 45 (45.0) | ||
| rs1130864 polymorphism | TT homozygous | 6 (5) | 14 (14) | 0.002 |
| CT heterozygous | 42 (35) | 48 (48) | ||
| CC homozygous | 72 (60) | 38 (38) | ||
| rs1800947 polymorphism | CC homozygous | 11 (9.2) | 7 (7) | 0.559 |
| CG heterozygous | 109 (90.8) | 93 (93) | ||
| rs1205 allele | T | 85 (35.4) | 72 (36) | 0.899 |
| C | 155 (64.6) | 128(64) | ||
| rs1130864 allele | T | 54 (22.5) | 76 (38) | <0.001 |
| C | 186 (77.5) | 124 (62) | ||
| rs1800947 allele | G | 109 (45.4) | 93 (46.5) | 0.82 |
| C | 131 (54.6) | 107 (53.5) | ||
Associations between the rates of rs1130864 polymorphism and sociodemographic characteristics, clinical features and laboratory results
| RS1130864 polymorphism | |||||
|---|---|---|---|---|---|
| TT homozygous | CT heterozygous | CC homozygous | P value | ||
| The age of first symptom (years), median (IQR) | 50(48–52) | 43.5(37–50) | 42(38–49.5) | 0.154a | |
| The age of diagnosis (years), median (IQR) | 56(52–58) | 47(38–54) | 47(42–52.5) | 0.061a | |
| Delay time of diagnosis (years), median (IQR) | 5.5(3–8) | 2(1–5) | 3(1–6) | 0.279a | |
| Smoking, n (%) | 0.448b | ||||
| + | 3(6.7) | 18(40) | 24(53.3) | ||
| − | 3(4) | 24(32) | 48(64) | ||
| Family history, n (%) | 0.714b | ||||
| + | 1(4.8) | 9(42.9) | 11(52.4) | ||
| − | 5(5.1) | 33(33.3) | 61(61.6) | ||
| Drug treatment, n (%) | 0.775b | ||||
| Biologic | 1(7.7) | 4(30.8) | 8(61.5) | ||
| DMARD | 5(4.7) | 38(35.5) | 64(59.8) | ||
| DAS-28 >5.1, n (%) | 0.793b | ||||
| + | 2(5.6) | 11(30.6) | 23(63.9) | ||
| − | 4(4.8) | 31(36.9) | 49(58.3) | ||
| The first CRP>0.8, n (%) | 0.625b | ||||
| + | 5(4.6) | 38(34.9) | 66(60.6) | ||
| − | 1(9.1) | 4(36.4) | 6(54.5) | ||
| The last CRP>0.8, n (%) | 0.659b | ||||
| + | 1(3.6) | 12(42.9) | 15(53.6) | ||
| − | 5(5.4) | 30(32.6) | 57(62) | ||
| RF, n (%) | 0.807b | ||||
| + | 5(5.4) | 34(36.6) | 54(58.1) | ||
| − | 1(3.7) | 8(29.6) | 18(66.7) | ||
| Anti-CCP, n (%) | 0.804b | ||||
| + | 3(3.8) | 29(37.2) | 46(59) | ||
| − | 2(6.9) | 11(37.9) | 16(55.2) | ||
| Presence of lung involvement, n (%) | 0.017c | ||||
| + | 3(20) | 4(26.7) | 8(53.3) | ||
| − | 3(2.9) | 38(36.2) | 64(61) | ||
| DAS 28 score, mean ± SD | 4.8±0.65 | 4.7±0.55 | 4.9±0.5 | 0.140d | |
| The first ESR (mm/h), median (IQR) | 40.5(21–59) | 34.5(24–51) | 39.5(28.5–53) | 0.314a | |
| The final ESR (mm/h), median (IQR) | 11.5(3–15) | 11(5–17) | 11.5(6–17.5) | 0.943a | |
| The first CRP, (mg/dl), median (IQR) | 7.5(4.3–30.7) | 2.6(1.7–5.1) | 2.8(1.4–4.9) | 0.162a | |
| The final CRP(mg/dl), median (IQR) | 0.2(0.1–0.5) | 0.5(0.3–0.9) | 0.5(0.2–0.7) | 0.339a | |
| RF (IU/ml), median (IQR) | 69(22–159) | 137(30–324) | 61(10–215) | 0.214a | |
| Anti CCP (IU/ml) median (IQR) | 122(11–74) | 84(15–815) | 20(18–1000) | 0.664a | |
CRP gene polymorphisms
| SNP ID | Localization | Context sequence | Phenotype | Polymorphism |
|---|---|---|---|---|
| rs1205 | Chromosome 1:159712443 | (C/T) | MIM:123260 | C/T Transition Substitution |
| rs1800947 | Chromosome 1:159713648 | (C/G) | MIM:123260 | C/G Transversion Substitution |
| rs1130864 | Chromosome 1:159713301 | (A/G) | MIM:123260 | A/G Transition Substitution |
Socio-demographic and clinical characteristics of the patient-group
| Age (years), mean ± SD | 56,4 ± 9.7 |
| Female sex, n (%) | 100 (83.3) |
| The age of first symptom (years), mean ± SD | 43,4 ± 9.7 |
| The age of diagnosis (years), mean ± SD | 47,2 ± 10.2 |
| Smoking, n (%) | 45 (37.5) |
| Family history, n (%) | 21 (17.5) |
| Drug treatment, n (%) | |
| Biologic | 13 (10.8) |
| DMARD | 107 (89.2) |
| DAS-28 >5.1, n (%) | 36 (30) |
| Presence of lung involvement, n (%) | 15 (12.5) |
| The first CRP>0.8, n (%) | 109 (91,2) |
| The last CRP>0.8, n (%) | 32 (26,3) |
| Autoantibodies | |
| RF, n (%) | 93 (77,5) |
| Anti-CCP, n (%) | 78 (72,9) |
| ANA, n (%) | 24 (22,0) |